Sysmex (OTCMKTS:SSMXY) Sees Strong Trading Volume – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw strong trading volume on Tuesday . 557,534 shares traded hands during trading, an increase of 256% from the previous session’s volume of 156,483 shares.The stock last traded at $9.89 and had previously closed at $9.72.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised shares of Sysmex from a “hold” rating to a “buy” rating in a report on Thursday, October 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Sysmex presently has an average rating of “Moderate Buy”.

Sysmex Price Performance

The company has a 50-day moving average of $10.52 and a 200 day moving average of $13.37. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $6.27 billion, a PE ratio of 19.92 and a beta of 1.17.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Wednesday, November 5th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $826.60 million for the quarter, compared to analysts’ expectations of $880.80 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. Sell-side analysts predict that Sysmex Corporation ADR will post 0.57 EPS for the current year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.